Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 17, Issue 2, pp 109–113 | Cite as

A new triphenylethylene compound, Fc-1157a

II. Antitumor effects
  • Lauri Kangas
  • Anna-Liisa Nieminen
  • Guillermo Blanco
  • Matti Grönroos
  • Sinikka Kallio
  • Arto Karjalainen
  • Milla Perilä
  • Marja Södervall
  • Reijo Toivola
Original Articles Antiestrogens, Fc-1157a, Tamoxifen, MCF-7, Antineoplastic Agents, Breast Cancer, Toremifene

Summary

The antitumor effects of a new antiestrogen, Fc-1157a1 have been studied in vitro and in vivo. In vitro the effect of Fc-1157a was comparable to that of tamoxifen. The effect was dose-dependent, and at concentrations higher than 10-6 mol/l Fc-1157a induced real cell death of the MCF-7 cells. In DMBA-induced mammary cancer in rats Fc-1157a decreased the number of new tumors and inhibited the growth of existing tumors, these effects being statistically highly significant. The ratio of growing tumors to stable and regressing tumors was significantly decreased. Although these effects were slightly stronger with Fc-1157a than with tamoxifen, the difference between these two compounds was not statistically significant.

Murine uterine sarcoma, an estrogen receptor-negative tumor, was resistant to tamoxifen, but was statistically significantly inhibited by high doses (100 and 200 mg/kg-1 day-1 for 5 days) of Fc-1157a.

The antitumor effects of Fc-1157a are due mainly to the antiestrogenic activity. At high concentrations in vitro and at high doses in vivo Fc-1157a exerts antitumor effects some of which are different from those of tamoxifen and are directed even against estrogen receptor-negative tumors. The exact mechanism of the observed cytolytic effect at high doses is unknown.

Keywords

Cell Death Estrogen Cancer Research Sarcoma Tamoxifen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Blackburn AM, Amiel SA, Millis RR, Rubens RD (1984) Tamoxifen and liver damage. Br Med J 289: 288Google Scholar
  2. 2.
    Butler WB, Kelsey WH, Goran N (1981) Effects of serum and insulin on the sensitivity of the human breast cancer cell line MCF-7 to estrogen and antiestrogen. Cancer Res 41: 82–88Google Scholar
  3. 3.
    Carbone PP: Breast cancer. In: Pinedo HM, Chabner BA (eds) Cancer chemotherapy 1983. The EORTC cancer chemotherapy annual, no 5. Elsevier Amsterdam, pp 398–422Google Scholar
  4. 4.
    Chen TR (1977) In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 104: 255–262Google Scholar
  5. 5.
    Grönroos M, Kangas L, Mäenpää J, Vanharanta R, Nieminen A-L, Johansson R (1984) Steroid receptors and response of ovarian cancer to hormones in vitro. Br J Obstet Gynaecol 91: 472–478Google Scholar
  6. 6.
    Jordan VC, Allen KE (1980) Evaluation of the antitumor activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16: 239–251Google Scholar
  7. 7.
    Jordan VC, Gosden B (1983) Inhibition of the uterotropic activity of estrogens and antiestrogens by the short-acting antiestrogen LY 117018. Endocrinology 113: 463–468Google Scholar
  8. 8.
    Kangas L, Nieminen A-L, Grönroos M (1984) Bioluminescence of cellular ATP: a new method for evaluation of cytotoxic agents in vitro. Med Biol 62: 338–343Google Scholar
  9. 9.
    Lippman M, Bolan G, Huff K (1976) The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595–4601Google Scholar
  10. 10.
    Rochefort H, Borgna JL, Evans E (1983) Cellular and nuclear mechanism of action of antiestrogens. J Steroid Biochem 19: 69–74Google Scholar
  11. 11.
    Rochefort H, Bardon S, Chalbos D, Vignon F (1984) Steroidal and nonsteroidal antiestrogens in breast cancer cells in culture. J Steroid Biochem 20: 105–110Google Scholar
  12. 12.
    Scholl SM, Huff KK, Lippman M (1983) Antiestrogenic effects of LY 117018 in MCF-7 cells. Endocrinology 113: 611–617Google Scholar
  13. 13.
    Sica G, Natoli C, Marchetti P, Piperno S, Iacobelli S (1984) Tamoxifen induced membrane alterations in human breast cancer cells. J Steroid Biochem 20: 425–428Google Scholar
  14. 14.
    Soule HD, Vazques J, Long A, Albert S, Brennan M (1973) A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409–1416Google Scholar
  15. 15.
    Sutherland RL, Murphy LC, Foo MS, Green MD, Mhybourne AM, Krozowski ZS (1980) High-affinity antiestrogen binding site distinct from the estrogen receptor. Nature 288: 273–275Google Scholar
  16. 16.
    Sutherland RL, Reddel RR, Green MD (1983) Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. Eur J Cancer Clin Oncol 19: 307–318Google Scholar
  17. 17.
    Tormey DC, Lippman ME, Edwards BK, Cassidy JG (1983) Evaluation of tamoxifen doses with and without fluoxymestrone in advanced breast cancer. Ann Intern Med 98: 139–144Google Scholar
  18. 18.
    Wakeling AE, Valcaccia B, Newboult E, Green LR (1984) Nonsteroidal antiestrogens-receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem 20: 111–120Google Scholar
  19. 19.
    Watanabe M, Tanaka H, Koizumi H, Tanimoto Y, Torii R, Yanagita T (1980) General toxicity studies of tamoxifen in mice and rats. Jitchuken Zenrinsho Kenkyuho 6: 1–36Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • Lauri Kangas
    • 1
  • Anna-Liisa Nieminen
    • 1
  • Guillermo Blanco
    • 2
  • Matti Grönroos
    • 3
  • Sinikka Kallio
    • 1
  • Arto Karjalainen
    • 1
  • Milla Perilä
    • 1
  • Marja Södervall
    • 1
  • Reijo Toivola
    • 1
  1. 1.Research CenterFarmos Group LTDTurku and OuluFinland
  2. 2.Department of Radiation TherapyOulu University Central HospitalFinland
  3. 3.Department of Obstetrics and GynecologyTurku University Central HospitalFinland

Personalised recommendations